Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Mar
15
Today In Oncology
Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males
p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
Disease Stage at Breast Cancer Diagnosis Impacted by Region Race and Insurance
Can Viral Respiratory Infections Increase Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo